Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer
- PMID: 12928124
- DOI: 10.1016/s0169-5002(03)00236-8
Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer
Abstract
Purpose: To determine local control and survival rates in 92 patients with 145 brain metastases treated with three options of radiotherapy including stereotactic radiosurgery (SR).
Methods: Between July 1994 and August 2002, 92 consecutive patients with 145 metastases were treated with a SR, 34 with initially SR alone, 22 initially with an association of whole-brain radiotherapy (WBRT) and 36 with SR alone for recurrent new brain metastasis after WBRT. At time of treatment, extracranial disease was controlled in 46 (50%) and uncontrolled in 46 (50%). Pathologies were adenocarcinoma in 54 cases (59%), squamous cell carcinoma in 14 cases (15%), small cell carcinoma in 10 cases (11%) and miscellaneous in 14 cases (15%). All patients underwent only one treatment fraction for 1 or 2 metastases in 73 cases (83%) and for more than 2 metastases for the others.
Results: The characteristics of patients and metastases in the group treated initially with SR alone and in the group treated initially with WBRT+SR were comparable. Median follow-up was 29 months (18-36). Overall, the median and the 1- and 2-year rates of overall survival were, respectively, 9 months, 37 and 20%. A controlled extracranial disease, a high Karnofsky index and a low number of metastasis were independent prognostic factor of overall survival, respectively, HR 0.53 (95% CI 0.31-0.90, P=0.01), HR 0.95 (95% CI 0.92-0.97, P=0.0002), and HR 0.48 (95% CI 0.25-0.90, P=0.02). Thirteen metastases were not controlled (9%). Six-month and 1-year local control rate were, respectively, 93 and 86%. High delivered dose was an independent prognostic factor of local control, HR 0.41 (95% CI 0.18-0.95, P=0.03). A controlled extracranial disease was favourable independent prognostic factor of brain free-disease free survival, HR 0.47 (95% CI 0.2-0.98, P=0.04). Although there was a trend of a better local control, overall and brain disease free survivals rates in the WBRT+SR group compared to SR alone one, the difference were not statistically different.
Conclusion: Local control and survival rates are acceptable for a palliative treatment for the three option of treatment. In this series, the number of patients is not enough great to conclude to the necessity of the association of WBRT to SR. Re-irradiation is a safe treatment after new metastases appeared in previously irradiated area.
Similar articles
-
Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases.Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34. doi: 10.1016/s0360-3016(99)00198-4. Int J Radiat Oncol Biol Phys. 1999. PMID: 10487566 Clinical Trial.
-
Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):303-9. doi: 10.1016/j.ijrobp.2011.06.1987. Epub 2011 Nov 11. Int J Radiat Oncol Biol Phys. 2012. PMID: 22079723
-
Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer.Anticancer Res. 2010 Jul;30(7):3055-61. Anticancer Res. 2010. PMID: 20683055 Clinical Trial.
-
Stereotactic radiosurgery (SRS) alone versus whole brain radiotherapy plus SRS in patients with 1 to 4 brain metastases from non-small cell lung cancer stratified by the graded prognostic assessment: A meta-analysis (PRISMA) of randomized control trials.Medicine (Baltimore). 2018 Aug;97(33):e11777. doi: 10.1097/MD.0000000000011777. Medicine (Baltimore). 2018. PMID: 30113464 Free PMC article. Review.
-
Clinical outcomes of stereotactic radiosurgery in the treatment of patients with metastatic brain tumors.World Neurosurg. 2011 May-Jun;75(5-6):673-83. doi: 10.1016/j.wneu.2010.12.006. World Neurosurg. 2011. PMID: 21704935 Review.
Cited by
-
Dose-effect relationship of linear accelerator based stereotactic radiotherapy for brain metastases.Radiat Oncol. 2023 Oct 30;18(1):177. doi: 10.1186/s13014-023-02360-y. Radiat Oncol. 2023. PMID: 37904212 Free PMC article.
-
Evaluation of results of linac-based radiosurgery for brain metastases from primary lung cancer.Rep Pract Oncol Radiother. 2013 Sep 3;19(1):19-29. doi: 10.1016/j.rpor.2013.06.006. eCollection 2014 Jan. Rep Pract Oncol Radiother. 2013. PMID: 24936316 Free PMC article.
-
Dose-Volume Response Relationship for Brain Metastases Treated with Frameless Single-Fraction Linear Accelerator-Based Stereotactic Radiosurgery.Cureus. 2016 Apr 27;8(4):e587. doi: 10.7759/cureus.587. Cureus. 2016. PMID: 27284495 Free PMC article.
-
Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery in the Treatment of Brain Metastases Leading to Improved Survival in Patients With Favorable Prognostic Factors.Front Oncol. 2019 Mar 29;9:205. doi: 10.3389/fonc.2019.00205. eCollection 2019. Front Oncol. 2019. PMID: 30984624 Free PMC article.
-
Factors associated with the local control of brain metastases: a systematic search and machine learning application.BMC Med Inform Decis Mak. 2024 Jun 21;24(1):177. doi: 10.1186/s12911-024-02579-z. BMC Med Inform Decis Mak. 2024. PMID: 38907265 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials